These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17056564)

  • 1. Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host.
    Belyakov IM; Isakov D; Zhu Q; Dzutsev A; Klinman D; Berzofsky JA
    J Immunol; 2006 Nov; 177(9):6336-43. PubMed ID: 17056564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
    Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
    J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
    McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
    J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.
    Kremer M; Suezer Y; Volz A; Frenz T; Majzoub M; Hanschmann KM; Lehmann MH; Kalinke U; Sutter G
    PLoS Pathog; 2012; 8(3):e1002557. PubMed ID: 22396645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
    Liu Y; Luo X; Yang C; Yu S; Xu H
    Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infections.
    Gunawardana T; Ahmed KA; Goonewardene K; Popowich S; Kurukulasuriya S; Karunarathna R; Gupta A; Lockerbie B; Foldvari M; Tikoo SK; Willson P; Gomis S
    Sci Rep; 2019 Jan; 9(1):341. PubMed ID: 30674918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
    Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
    J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
    Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
    J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines.
    Green S; Ennis FA; Mathew A
    Vaccine; 2011 Feb; 29(8):1666-76. PubMed ID: 21195803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments
    de Freitas LFD; Oliveira RP; Miranda MCG; Rocha RP; Barbosa-Stancioli EF; Faria AMC; da Fonseca FG
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
    J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx.
    Abe N; Kodama S; Hirano T; Eto M; Suzuki M
    Laryngoscope; 2006 Mar; 116(3):407-12. PubMed ID: 16540899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
    Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.
    Berhanu A; King DS; Mosier S; Jordan R; Jones KF; Hruby DE; Grosenbach DW
    Vaccine; 2010 Dec; 29(2):289-303. PubMed ID: 21036130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and humoral immunity against vaccinia virus infection of mice.
    Xu R; Johnson AJ; Liggitt D; Bevan MJ
    J Immunol; 2004 May; 172(10):6265-71. PubMed ID: 15128815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.